Mechanistic description
We hypothesize that in early Alzheimer’s disease (CDR 0.5-1), the anterior thalamic nuclei develop functional hyperconnectivity with hippocampal circuits as a compensatory response to entorhinal cortex degeneration, preserving episodic memory function. However, this hyperconnectivity creates a metabolically vulnerable state where increased neuronal activity elevates extracellular adenosine through ectonucleotidase pathways, suppressing synaptic efficacy and promoting amyloid-beta oligomerization at hyperconnected synapses. The transition from hyper-to hypo-connectivity marks a point of metabolic failure where compensatory mechanisms become pathological drivers. Testable predictions: (1) anterior thalamic nuclei will show increased functional connectivity correlated with preserved hippocampal CA1 activity in early AD; (2) microdialysis studies will reveal elevated extracellular adenosine at hyperconnected thalamic-hippocampal synapses; (3) PET amyloid burden will preferentially accumulate in thalamic hub regions exhibiting early hyperconnectivity; (4) inhibition of adenosine A1 receptors in mouse models will accelerate the hyper-to-hypoconnectivity transition and worsen cognitive outcomes.
Mechanism / pathway
- ENTPD1
- Adenosine-mediated neuromodulation and metabolic coupling
- Alzheimer's disease
Evidence for (5)
Minimal clinically important difference in Alzheimer's disease: Rapid review.
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3.
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Clinical progression on CDR-SB©: Progression-free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations.
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
Evidence against (2)
Evidence matrix
Supporting
- Minimal clinically important difference in Alzheimer's disease: Rapid review. PMID:38561021 · 2024 · Alzheimers Dement
- Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3. PMID:40955720 · 2025 · Alzheimers Dement
- Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension. PMID:41330788 · 2026 · J Prev Alzheimers Dis
- Clinical progression on CDR-SB©: Progression-free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations. PMID:40911712 · 2025 · Alzheimers Dement
- Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB. PMID:37101394 · 2023 · CPT Pharmacometrics Syst Pharmacol
Contradicting
No contradicting evidence recorded.
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund signals
from 1 contributing personas in log-odds space, weighted
by uniform. Prior 50%.
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Thalamic anterior nucleus hyperconnectivity drives early-stage functional compe…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-4bc00f3610
@misc{scidex_hypothesis_h4bc00f3,
title = {Thalamic anterior nucleus hyperconnectivity drives early-stage functional compe…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-4bc00f3610},
note = {SciDEX artifact hypothesis:h-4bc00f3610}
}